Article Text

Download PDFPDF
Definitive Chemoradiotherapy in Elderly Cervical Cancer Patients: A Multiinstitutional Analysis
  1. Ozan Cem Guler, MD*,
  2. Sezin Yuce Sari, MD,
  3. Sumerya Duru Birgi, MD,
  4. Melis Gultekin, MD,
  5. Ferah Yildiz, MD and
  6. Cem Onal, MD§
  1. * Department of Radiation Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon;
  2. Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara;
  3. Department of Radiotherapy, Gazi Yasargil Training and Research Hospital, Diyarbakir; and
  4. § Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana, Turkey.
  1. Address correspondence and reprint requests to Ozan Cem Guler, MD, Department of Radiation Oncology, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey. E-mail: ocguler{at}gmail.com.

Abstract

Objective The aim of the study was to investigate the prognostic factors for survival and treatment-related toxicities in older (≥65 years) cervical cancer patients treated with definitive chemoradiotherapy. In addition, we sought to compare the outcomes between the older elderly (≥75 years) and their younger old counterparts (age, 65–74 years).

Materials and Methods We retrospectively reviewed medical records from 269 biopsy-proven nonmetastatic cervical cancer patients treated with external radiotherapy and intracavitary brachytherapy at the departments of radiation oncology in 2 different universities. The prognostic factors for survival, local control, and distant metastasis (DM) were analyzed.

Results The median follow-up time was 38.8 months (range, 1.5–175.5 months) for the entire cohort and 70.0 months (range, 6.1–175.7 months) for survivors. The 2- and 5-year overall survival (OS), disease-free survival (DFS), and cause-specific survival rates were 66% and 42%, 63% and 39%, and 72% and 55%, respectively. Patients 75 years or older showed significantly worse OS compared with patients aged 65 to 74 years but showed no significant difference in DFS. The 2- and 5-year local control rates were 86% and 71%, respectively. The incidences of DMs at 2 and 5 years were 22% and 30%, respectively. In multivariate analysis, vaginal infiltration and lymph node metastasis were predictive of OS, DFS, local recurrence, and DM. Concomitant chemotherapy was predictive of OS, DFS, and local recurrence, and larger tumor (>4 cm) was a significant prognostic factor for local recurrence. None of the patients had toxicity that necessitated the discontinuation of radiotherapy. All patients were evaluable for acute toxicity, and no grade higher than 3 adverse events occurred during external beam radiation therapy or brachytherapy.

Conclusions Although age limited the delivery of aggressive treatment, concurrent chemoradiotherapy in elderly patients associated with improved outcomes similar as in younger counterparts without increasing serious acute and late toxicities.

  • Cervical cancer
  • Older age
  • Chemoradiotherapy
  • Prognostic factors

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.